gsk189254
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00387413)
Timeline
Indications
Studied for
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Ph 2 trial terminated
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1- Mol. weight
- 351.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL517140 ↗
Also known as
- 6-((3-cyclobutyl-2,3,4,5-tetrahydro-1h-3-benzazepin-7-yl)oxy)-n-methyl-3-pyridinecarboxamide
- gsk189254
- gsk189254
- gsk189254
- gsk189254
- gsk 189254
- gsk-189254
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00366080 | Phase 2 | Nov 1, 2006 | GlaxoSmithKline |
| NCT00387413 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2006 |
1 organizations
Page 1 / 1